{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/scarlet-fever/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"8484304f-9507-5401-8c08-2c93126a8b3f","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field 6ec29665-f47d-43f3-abc2-c6eaca0d7d5e --><h2>When should I suspect a diagnosis of scarlet fever?</h2><!-- end field 6ec29665-f47d-43f3-abc2-c6eaca0d7d5e -->","summary":"","htmlStringContent":"<!-- begin item 2207679c-fa6f-4f11-bd4a-a6df03a89e12 --><!-- begin field 5af44afc-a162-476f-877a-56bddd5358ca --><p><strong>Suspect a diagnosis of scarlet fever if there are typical clinical features present.</strong></p><ul><li><strong>Initial clinical features may be non-specific and include: </strong><ul><li>Sore throat. </li><li>Fever (typically greater than 38.3°C). </li><li>Headache, fatigue, nausea, and vomiting. </li></ul></li><li><strong>A blanching rash usually develops on the trunk 12–48 hours after initial symptoms, before spreading to the rest of the body and flexures. </strong><ul><li>The rash is characteristically red, generalized and pinpoint (punctate) with a rough, sandpaper-like texture.</li><li>It may be accentuated in the skin folds of the neck, axillae, groin, elbows, and knees with a deep red, linear appearance (so-called 'Pastia's lines').</li><li>The palms and soles are typically spared.</li><li>The skin may peel after the rash resolves, particularly at the tips of the fingers and toes, and less commonly on the trunk and limbs.</li></ul></li><li><strong>Examination may also reveal: </strong><ul><li>Strawberry tongue — initially the tongue is covered with a white coat through which red papillae may be seen. Later, the white covering disappears, leaving the tongue with a beefy red appearance. </li><li>Associated cervical lymphadenopathy. </li><li>Flushed face, with marked circumoral pallor. </li><li>Pharyngitis and small red spots (petechiae) on the hard and soft palate ('Forchheimer spots').</li></ul></li><li><strong>Be alert for clinical features of scarlet fever in people who are at <a class=\"topic-reference internal-reference\" href=\"/topics/scarlet-fever/background-information/risk-factors/\">increased risk</a> of invasive Group A streptococcal (iGAS) infection and its <a class=\"topic-reference internal-reference\" href=\"/topics/scarlet-fever/background-information/complications/\">complications</a>.</strong></li><li><strong>Consider an <a class=\"topic-reference internal-reference\" href=\"/topics/scarlet-fever/diagnosis/differential-diagnosis/\">alternative diagnosis</a> if symptoms and signs are atypical, particularly in older children and adults.</strong></li></ul><!-- end field 5af44afc-a162-476f-877a-56bddd5358ca --><!-- end item 2207679c-fa6f-4f11-bd4a-a6df03a89e12 -->","topic":{"id":"7c05f7c5-902d-5982-8cc9-5f1d301d214d","topicId":"f534013d-38dd-4f96-bc65-37091262952c","topicName":"Scarlet fever","slug":"scarlet-fever","lastRevised":"Last revised in March 2020","chapters":[{"id":"d3f6c278-a759-50f3-9a96-734913f439ab","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ffff4a88-7ddf-55dc-a37b-1625f3f58e2b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"89be33c0-acbe-51fd-901b-d7cf571435a4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61377ddb-df7a-50fb-9dd7-224014332a4e","slug":"changes","fullItemName":"Changes"},{"id":"b5e95aca-9003-52f8-b6e7-0c192c5ba757","slug":"update","fullItemName":"Update"}]},{"id":"90d2085f-63f5-57a1-b21e-21d4c580229a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cc3aa630-ef6b-5504-9439-6a4757e7fe43","slug":"goals","fullItemName":"Goals"},{"id":"ebf64432-58f2-513f-a393-ec4e8438f355","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b3da9abe-7cc8-5c97-970d-39b1416de8cb","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8b3309e1-1d9f-520e-b310-592706c0951d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0603af50-edd7-5e78-a394-1fd6a1a1af21","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00da52ed-356a-563d-aa3c-dc4e3ee27155","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7072120a-72ec-5945-b4f0-e4386374e1ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f61354f7-80ff-5483-89fc-51be1d57b5d3","slug":"definition","fullItemName":"Definition"},{"id":"4dc22989-c1d3-5880-a381-78cabd38ca4d","slug":"transmission","fullItemName":"Transmission"},{"id":"c4e4e4ff-9b93-5d55-8ae0-5e0b1a518ef3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"5b31f083-75b7-5ae3-9029-87df9bc061cf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"94ffb885-96f6-595f-b1ad-fb146a27db30","slug":"complications","fullItemName":"Complications"},{"id":"f3bf38a0-7946-504a-b22c-654728a0366a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ffb84f0d-77eb-5011-a50d-14d9143e4bd4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8484304f-9507-5401-8c08-2c93126a8b3f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"601ddd63-7670-5740-a0f6-fe317e0d7770","slug":"investigations","fullItemName":"Investigations"},{"id":"a1df37ba-9251-52d5-8376-b19803e39cc3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5329e2f2-3618-5113-8fc1-5228ff864869","fullItemName":"Management","slug":"management","subChapters":[{"id":"963d805b-33a2-5e78-9195-323379519c7e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db4a097c-9d97-5e1e-8718-e082e8e25f5e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4a26593a-c9e4-5523-a6d2-5feb274dcf79","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"},{"id":"2a494a84-0688-5337-8f03-a2ab33a654fb","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"ce256942-e7de-5014-bdf7-f34be5755538","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"7e3b4438-f437-5199-8ee5-f3c9d210b732","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f2446794-c34e-574f-8de3-c5ecbe3c4f35","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1a90ff7f-b2b6-5959-86a0-3cea6609706f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d14df6f-1299-58da-b620-c970e5b90b91","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"db42b54d-b095-52b7-9cb1-37d73c57fdb7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"551dac2a-e65d-57c4-b16c-279891510a2b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5d76e530-4218-5600-a9ed-896a3245aefb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"03221ed8-00f7-5819-b90c-cc69c4a1fdb8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ffb84f0d-77eb-5011-a50d-14d9143e4bd4","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"72ad2b8f-6d61-5a16-99b9-8f395dba7d85","slug":"basis-for-recommendation-da9","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field f8fa7e68-dc7f-40e4-849a-f03c56e2ae05 --><h3>Basis for recommendation</h3><!-- end field f8fa7e68-dc7f-40e4-849a-f03c56e2ae05 -->","summary":null,"htmlStringContent":"<!-- begin item da91d058-0fbc-4ae9-aab2-224e86619a16 --><!-- begin field e51cf8c0-6fd2-4fbc-9185-c78fae31051c --><p>The recommendations on when to suspect scarlet fever are based on expert opinion in the Public Health England (PHE) publication <em>Guidelines for the public health management of scarlet fever outbreaks in schools, nurseries and other childcare settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">PHE, 2017</a>], and expert opinion in review articles on scarlet fever [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Wong, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Holden, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Basetti, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">DTB, 2018</a>], information in a medical textbook on streptococcal pharyngitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Wessels, 2016</a>], and information in an infectious diseases textbook on scarlet fever [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Bisno, 2010</a>].</p><ul><li>The information that scarlet fever is diagnosed on the basis of clinical features is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Holden, 2015</a>].</li><li>The information on the typical features of the rash and other clinical features are based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Holden, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Basetti, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">DTB, 2018</a>] and in a medical textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Wessels, 2016</a>].</li><li>The recommendation to be aware of the possiblility of scarlet fever and invasive Group A streptococcal (iGAS) infection in people at high risk is based on the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">PHE, 2017</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">DTB, 2018</a>].<ul><li>PHE recommends that healthcare professionals have a high level of suspicion of scarlet fever and streptococcal throat infection in this high-risk group to allow rapid diagnosis and treatment, to reduce the risk of iGAS. It notes the increased risk of iGAS disease, especially when there are concomitant outbreaks of chickenpox or influenza with GAS infection. It states that chickenpox is the most common risk factor for iGAS disease in children, and influenza is another risk factor for iGAS disease more generally.</li></ul></li></ul><!-- end field e51cf8c0-6fd2-4fbc-9185-c78fae31051c --><!-- end item da91d058-0fbc-4ae9-aab2-224e86619a16 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}